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Three adult (≥18 years) cohorts from The Epidemiology and
Natural History of Asthma: Outcomes and Treatment Regimens
(TENOR) 3-year observational study were deﬁned: patients on
SFC Low-Dose (100/50 or 250/50 μg), patients on SFC High-
Dose (500/50 μg), and patients on other medications (including
salmeterol and ﬂuticasone), but not on SFC. Using standard
regression methods, we computed unadjusted and propensity
score adjusted differences in 24 month outcomes between the
treatment cohorts. RESULTS: After adjustment for confounding,
the Low-Dose SFC cohort had higher asthma-related quality of
life (P = 0.0026), fewer asthma control problems (P = 0.0001),
similar rates of exacerbations (P = 0.8932), marginally higher
FEV1 (P = 0.0777) and lower odds of having severe asthma (P
= 0.0454) compared with controls (patients never on SFC). After
adjustment for confounding, the High-Dose SFC cohort had no
difference in asthma-related quality of life, asthma control prob-
lems, or exacerbation rates (P = 0.1879, 0.3015, 0.3560 respec-
tively), higher FEV1 (P = 0.0011), and higher odds of having
severe asthma (P = 0.0137). CONCLUSIONS: The results
support evidence that some asthmatics achieve better control
while taking low-dose SFC, but also suggest that high-dose SFC
fails to provide clinically signiﬁcant beneﬁt in terms of most
asthma-related health outcomes when compared to similar
patients not taking high-dose SFC. These ﬁndings may highlight
an unmet need in severe or difﬁcult-to-treat asthma and call for
alternative therapeutic approaches in those unable to attain
asthma control with or without SFC.
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EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER
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OBJECTIVES: Asthma exacerbation rates in a large Midwest
health plan were compared for single and dual controllers.
METHODS: The asthma cohort included 788 patients pre-
scribed at least 1 SABA and 2 controller prescriptions during a
6 month intake period, with mild persistent severity deﬁned by
rates of ED or hospital admission, SABA and OCS ﬁlls. Patients
older than age 55, diagnosed with COPD or prescribed more
than one type of controller were excluded. Exacerbations were
deﬁned by Kaplan-Meier, as time to asthma-related hospital or
ED admission. Signiﬁcance was further tested using Cox pro-
portional hazards stratiﬁed by age, gender, control, severity, and
adherence during a six-month pre-index period. RESULTS:
Leukotriene modiﬁers (LM) were prescribed as a single con-
troller for 38% of patients, inhaled corticosteroid (ICS) for 27%,
and dual controller (DC, ﬂuticasone/salmeterol) for 36%. DC
were prescribed most often in older adults (55%), while LM
were most often prescribed in children (62%). Asthma severity
as deﬁned by the number of SABA and OCS ﬁlls and exacerba-
tions in the intake period was similar for the three cohorts.
Asthma control (>4x controller/SABA) was highest for LM
(89%). Controller adherence rates were lowest in the ICS cohort
with 76% ﬁlling <4 prescriptions compared to 53% for DC and
44% for LM. Two-year exacerbation rates were 19% for ICS,
20% for LM and 18% for DC (P = 0.99). In the multivariate
model, older adults less likely suffered exacerbations compared
to children (hazard ratio = 0.63, 95% CI 0.44–0.91, P = 0.013).
CONCLUSION: An algorithm was developed to identify
patients with mild-persistent asthma in administrative claims.
Multivariate models were constructed to control for demo-
graphics, asthma severity, control and adherence rates. Kaplan-
Meier statistics indicates exacerbation rates were highest among
children, but were similar in patients receiving LM, ICS or DC.
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OBJECTIVES: To examine risk factors associated with health
care utilization in Arizona Medicaid patients with asthma.
METHODS: Data were obtained from Arizona Medicaid
between 1/1/2002 and 12/31/2003. Inclusion criteria consisted
of persons with an asthma diagnosis (ICD9-CM 493.xx), 5–62
years of age; and were new users of inhaled-corticosteroids (ICS),
combination ICS+long-acting beta-agonist, or leukotriene-
modiﬁers. Factors examined included age, geographic location
(urban/rural), race/ethnicity (White, non-Hispanic Black, His-
panic, other), medication adherence, pre-period short-acting
beta-agonist use (SABA), and co-morbidities. Utilization mea-
sures examined included post-period SABA use, exacerbations
measured by emergency-room or hospital visits, asthma-related
and total health care costs. Analyses for utilization measures
were performed using negative binomial, logistic regression, and
generalized linear modeling gamma-family, log-link, respectively.
RESULTS: A total of 3013 subjects met inclusion/exclusion cri-
teria and had a mean age (+SD) of 24.7 + 13.7 years. Urban res-
idents were 54% more likely to have an exacerbation than rural
residents (odds ratio-OR 0.46, 95%CI: 0.30–0.79). Age (years
18–39) was a signiﬁcant predictor across all analyses: SABA use
(incidence rate ratio-IRR 1.24, 95%CI: 1.06–1.44); exacer-
bations (OR 2.22, 95%CI: 1.34–3.68); mean asthma cost
($702.47, 95%CI: $600.07–822.34); mean total health care cost
($5445.67, 95%CI: $4852.18–6111.76). Age (years 40–62) sig-
niﬁcantly predicted mean total health care cost: $5662.88,
95%CI: $4814.67–6660.53. Males were 47% less likely to have
an exacerbation than females (OR 0.53, 95%CI: 0.30–0.91).
Exacerbations were not different between race/ethnicity cate-
gories. Predicted mean asthma-related costs were not different
between Whites ($590.65, 95%CI: 508.80–565.68), Blacks
(637.68, 95%CI: 499.10–814.75), or Hispanics (534.79,
95%CI: 466.14–613.55). CONCLUSION: Results of these
analyses found urban areas had higher rates of asthma-related
hospital visits compared to rural counties, but no signiﬁcant dif-
ference in asthma-costs between urban and rural areas. Persons
with asthma aged 18–39 had higher rates of asthma-related
emergency-room visits/hospitalizations and costs than those aged
5–17 and 40–62. Race/ethnicity was not a signiﬁcant predictor
of outcomes or asthma-related costs.
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OBJECTIVES: To review the health economic literature for
drugs that have since been withdrawn for safety reasons. To
assess the cost-effectiveness of the non-sedating anti-histamine,
terfenadine (withdrawn in 1998 for its cardiotoxicity) compared
with chlorpheniramine, a sedating anti-histamine which is still
available. METHODS: Literature searches of economic evalua-
tions of drug that have been withdrawn since 1980 were 
conducted. A decision analysis comparing terfenadine with
chlorpheniramine was developed. Observational data were
obtained for estimates of the incidence of ventricular dysryth-
mias, the incidence of serious injuries as a consequence of seda-
tion with chlorpheniramine, and the risk of death resulting from
arrhythmias or serious injuries. Health state utilities and data on
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clinical effectiveness were obtained from published sources. A
12-month time horizon was adopted, with probabilistic sensi-
tivity analysis and threshold analyses conduced to assess the
impact of uncertainty in parameter estimates. RESULTS: Exam-
ples of published cost-effectiveness analyses included troglita-
zone (PPAR activator, withdrawn in 2000 for hepatotoxicity),
and rofecoxib (COX-2 inhibitor, withdrawn in 2004 for cardio-
vascular toxicity). Despite including ADRs in the analyses, both
drugs were deemed cost-effective. The analysis of treatments for
allergic rhinitis revealed that, in fact, chlorpheniramine had a less
favourable risk/beneﬁt ratio than terfenadine, with a mean dif-
ference of 3.5 QALYs per 1000 patients (95% credible interval,
0.3, 7.6). Threshold analysis suggested that it would require the
relative risk of serious injury with terfenadine, compared with
chlorpheniramine, to increase from 45% to 85%, or for the efﬁ-
cacy of terfenadine to reduce from 60% to 34% for the decision
to be reversed. CONCLUSION: The inclusion in economic eval-
uations of ADRs that are deemed too hazardous to warrant
market authorisation by regulators, may lead to counter-intuitive
estimates of cost-effectiveness. This may be the fault of regula-
tors for not adopting decision analytic models, or reﬂect a lack
of risk aversion in economic evaluations. Alternative explana-
tions are explored.
ALLERGY/ASTHMA—Cost Studies
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RELIEVER THERAPY IN ASTHMA (SMART) COMPARED TO
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OBJECTIVES: To compare the cost-effectiveness of budes-
onide/formoterol in a single inhaler used as Maintenance and
Reliever Therapy (SMART) versus ﬁxed-dose ﬂuticasone/salme-
terol (FD) plus as-needed terbutaline reliever or ﬁxed higher-dose
budesonide/formoterol (FHD) plus as-needed terbutaline reliever
in controlling asthma in adults and adolescents. METHODS:
An economic evaluation was conducted based on the results 
of a large (N = 3335) RCT in which health resource utiliza-
tion was prospectively collected. Primary outcome measure-
ments included time to ﬁrst exacerbation and the number of
severe exacerbations. Costs included direct medical costs (physi-
cian/emergency room visits, hospitalizations, asthma drug costs)
and productivity (absenteeism). The time horizon was six-
months which corresponded to the duration of the trial. Prices
were obtained from 2006 Canadian sources. Both health care
(HC) and societal (Soc) perspectives were considered. Determin-
istic univariate sensitivity analyses were conducted. RESULTS:
In the clinical trial, SMART was superior to FD (p < 0.001) and
FHD (p = 0.0048). Exacerbation rates (reported as per patient
per 6 months) were 0.12 for SMART, 0.19 for FD, and 0.16 for
FHD. All treatments provided similar improvements in lung
function, asthma control days and asthma-related quality of life.
From the HC perspective, the mean cost per patient per 6 months
was $583 in the SMART arm versus $867 in the FD arm versus
$737 in the FHD arm. From the Soc perspective, it was $633 for
SMART, $914 for FD and $799 for FHD. SMART was domi-
nant (more effective, less expensive) in the base case analysis
from both the HC and Soc perspectives. The results were robust
under sensitivity testing. CONCLUSION: The SMART strategy
which allows budesonide/formoterol to be used as both mainte-
nance and reliever medication is dominant over a strategy of
ﬁxed dose salmeterol and ﬂuticasone plus as-needed terbutaline
and ﬁxed higher dose budesonide and formoterol plus as-needed
terbutaline.
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INFLAMMATION MONITOR IN THE DIAGNOSIS AND
MANAGEMENT OF ASTHMA IN THE US
Berg J, Lindgren P
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OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a
marker for the airway inﬂammation underlying asthma. NIOX
is a non-invasive, user-friendly FENO monitor that can be used
in physicians’ ofﬁces to provide immediate information on
patient response to anti-inﬂammatory treatment. The objective
of this study was to assess the cost-effectiveness of NIOX in
asthma diagnosis and management in the US. METHODS: Based
on a literature review, two decision trees were constructed to
capture the different alternatives and consequences in asthma
diagnosis and management, comparing FENO measurement
against standard diagnostics and treatment guidelines. The
impact of asthma management with FENO measurement on
resource use and health outcomes was evaluated over a 1-year
timeframe. A US payer perspective was chosen, using 2006 costs
from standard sources. Effectiveness was measured in quality-
adjusted life-years (QALYs). RESULTS: Asthma diagnosis based
on NIOX results in a cost of $29 per patient, including the cost
of false diagnoses, compared to $49 for standard diagnostics
(spirometry, reversibility testing, bronchoprovocation, sputum
eosinophil count). In mild to severe patients, asthma manage-
ment with FENO measurement instead of spirometry leads to
0.06 QALYs gained and cost-savings of $350 per patient and
year, of which $295 stem from reduced hospitalisations and $5
from lower doses of inhaled corticosteroids (ICS). In a more
severe population, management with NIOX would save $1350
($1250 from hospitalisations and $55 from reduced ICS doses)
and 0.004 QALYs per patient. Based on four visits per year, the
cost of monitoring would be reduced by $50 per patient with
NIOX. CONCLUSION: Asthma diagnosis based on NIOX
alone is less costly and more accurate than standard diagnostic
methods. The use of FENO measurement in treatment decisions
is less costly than asthma management based on standard guide-
lines and provides similar health beneﬁts.
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OBJECTIVES: Studies in patients with asthma and COPD have
demonstrated that levalbuterol (LEV) treatment resulted in sig-
niﬁcantly fewer nebulizations and/or decreased total cost of care
compared with racemic albuterol (RAC). This was a prospective,
multicenter, open-label study in patients hospitalized for acute
bronchospasm that evaluated the cost-effectiveness of the two
treatments. METHODS: Patients were randomized to either
LEV 1.25 mg (N = 241) Q8h or RAC 2.5 mg (N = 238), admin-
istered per routine standing hospital order. The primary endpoint
was the total number of nebulizations (scheduled plus rescue)
during hospitalization. Secondary endpoints included length and
cost of hospital stay. Cost-effectiveness (CE) analyses were con-
